Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Floats Eliminating Multi-Ingredient Pediatric Cold Products

This article was originally published in The Tan Sheet

Executive Summary

FDA suggests the drug industry consider making pediatric cough/cold formulations available only as single-ingredient products, according to an agency report

You may also be interested in...



FDA Urged To Change OTC Monograph System, But Not In Midstream

“Moving away from the monograph system when we are so close to the end” would “risk setting back the OTC drug review many years or even decades,” CHPA head Scott Melville says at an FDA public hearing. Other stakeholder s explain how the monograph system has failed industry and consumers.

FDA Urged To Change OTC Monograph System, But Not In Midstream

“Moving away from the monograph system when we are so close to the end” would “risk setting back the OTC drug review many years or even decades,” CHPA head Scott Melville says at an FDA public hearing. Other stakeholder s explain how the monograph system has failed industry and consumers.

J&J Ready To Capitalize On Zyrtec OTC Launch As Allergy Drug Hits Shelves

Johnson & Johnson's consumer product business is positioned to capitalize on the launch of nonprescription Zyrtec (cetirizine HCl) allergy medicine, J&J CEO Bill Weldon said during the firm's year-end analyst meeting Jan. 22

Related Content

Topics

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel